Table 5 Characteristics of GEO Datasets Included in the Study

From: A machine learning–enabled blood transcriptomic signature for digital diagnosis and subtyping of Alzheimer’s disease

Dataset

Region

Platform

Total N (AD / NC)

Mean Age (AD / NC)

Male ratio (AD / NC)

Sample Type

Brain Region

Diagnosis Criteria

Function

GSE5281

USA

GPL570

161 (87/74)

79.79/79.51

57.47%/71.62%

brain

Entorhinal Cortex /Hippocampus /Medial Temporal Gyrus /Posterior Cingulate /Superior Frontal Gyrus /Posterior Cingulate /Primary Visual Cortex

Clinical diagnosis+Braak stage+MMSE

Training Cohort

GSE84422

USA

GPL96/ GPL97/ GPL570

62 (34/28)

88.15/82.07

0%/57.14%

brain

Amygdala/Nucleus Accumbens

Clinical diagnosis + Braak stage + CERAD

Training Cohort

GSE122063

USA

GPL16699

100 (56/44)

78.6/80.9

33%/50%

brain

Frontal cortex/Temporal cortex

Clinical diagnosis + autopsy

Testing Cohort

GSE132903

Arizona

GPL10558

195 (97/98)

85.02/84.98

51.5%/51.0%

brain

Middle temporal gyrus

Clinical diagnosis + Braak stage + MMSE

Testing Cohort

GSE28146

USA

GPL570

30 (22/8)

86.38/86.27

27.27%/75%

brain

Hippocampal specimens

Clinical diagnosis + Braak stage + MMSE

Testing Cohort

GSE48350

USA

GPL570

253 (80/173)

89.22/80.71

41.25%/52.60%

brain

Postcentral gyrus/Superior frontal Gyrus/Hippocampus/Entorhinal cortex

Clinical diagnosis + Braak stage + MMSE

Testing Cohort

GSE36980

Japan

GPL6244

80 (33/47)

93.06/78.30

43.75%/43.48%

brain

Frontal cortex/Temporal cortex/Hippocampus

Clinical diagnosis + Braak stage

Testing Cohort

GSE37263

Singapore

GPL5175

16 (8/8)

72.63/80.15

62.5%/62.5%

brain

Neocortex

Clinical diagnosis + autopsy

Testing Cohort

GSE29378

USA

GPL6947

63 (31/32)

77.3/81.7

52.94%/68.75%

brain

Hippocampus

Clinical diagnosis + Braak stage

Testing Cohort

  1. GEO Gene Expression Omnibus, AD Alzheimer’s disease, NC normal controls, MMSE Mini-Mental State Examination, CERAD Consortium to Establish a Registry for Alzheimer’s Disease.